Elbasvir/grazoprevir
| Combination of | |
|---|---|
| Elbasvir | NS5A inhibitor |
| Grazoprevir | NS3/4A protease inhibitor |
| Clinical data | |
| Trade names | Zepatier |
| AHFS/Drugs.com | entry |
| Legal status |
|
| Routes of administration | Oral (tablets) |
| Identifiers | |
| ATC code | J05AX68 (temporary) |
Elbasvir/grazoprevir (trade name Zepatier ZEP-ah-teer) is a fixed-dose two drug combination for the treatment of hepatitis C, containing 50 mg elbasvir (a hepatitis C virus NS5A inhibitor) and 100 mg grazoprevir (an NS3/4A protease inhibitor). It is used to treat chronic HCV genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients.[1]
Both elbasvir and grazoprevir were developed by Merck & Co. The drug was approved on January 28, 2016.[2]
References
- ↑ "ZEPATIER™ (elbasvir and grazoprevir) Tablets, for Oral Use. Full Prescribing Information" (PDF). Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Retrieved 31 January 2016.
- ↑ "FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4". U.S. Food and Drug Administration. Retrieved 31 January 2016.
External links
| ||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Sunday, January 31, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.